Talphera (TLPH) Cash from Investing Activities (2010 - 2026)
Talphera's (TLPH) quarterly Cash from Investing Activities came in at -$2.7 million in Q1 2026, down 178.21% quarter-over-quarter from $3.5 million in Q4 2025.
Talphera (TLPH) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Talphera's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$2.7 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to -$2.7 million in Q1 2026; TTM through Mar 2026 was -$17.1 million, a 362.0% decrease from a year earlier, with the FY2025 full-year figure at -$14.3 million, down 479.4% from the prior year.
- Cash from Investing Activities fell to -$2.7 million in Q1 2026 per TLPH's latest filing, from $3.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $20.2 million in Q1 2022 and bottomed at -$17.8 million in Q3 2025.
- The 5-year median for Cash from Investing Activities is $2.7 million (2022), against an average of $1.7 million.
- Across the five-year window, Cash from Investing Activities jumped 283.28% in 2022 and slumped 3069.17% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at $2.7 million in 2022, then sank by 237.26% to -$3.7 million in 2023, then soared by 116.43% to $600000.0 in 2024, then jumped by 478.33% to $3.5 million in 2025, then sank by 178.21% to -$2.7 million in 2026.
- Per Business Quant, the three latest TLPH Cash from Investing Activities figures stand at -$2.7 million (Q1 2026), $3.5 million (Q4 2025), and -$17.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Talphera | 90.77 Mn | 90.77 Mn | - | -2.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.71 Mn |
| Mar 31, 2026 | -2.71 Mn |
| Dec 31, 2025 | 3.47 Mn |
| Dec 31, 2025 | 3.47 Mn |
| Sep 30, 2025 | -17.82 Mn |
| Sep 30, 2025 | -17.82 Mn |
| Sep 30, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 5.91 Mn |
| Jun 30, 2024 | 5.91 Mn |
| Mar 31, 2024 | -2.73 Mn |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | -3.65 Mn |
| Dec 31, 2023 | -3.65 Mn |
| Jun 30, 2023 | 2.72 Mn |
| Jun 30, 2023 | 2.72 Mn |
| Mar 31, 2023 | 400,000.00 |
| Mar 31, 2023 | 400,000.00 |
| Dec 31, 2022 | 2.66 Mn |
| Dec 31, 2022 | 2.66 Mn |